- Home
- ICG vs MREO Comparison
ICG vs MREO Comparison
Compare ICG & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICG | MREO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 50.3M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ICG | MREO |
|---|---|---|
| Price | $0.99 | $0.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $5.25 | $1.50 |
| AVG Volume (30 Days) | 146.9K | ★ 5.2M |
| Earning Date | 05-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | $6.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.20 |
| 52 Week High | $2.28 | $2.37 |
Technical Indicators
Market Signals| Indicator | ICG | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 61.36 | 43.24 |
| Support Level | $0.93 | $0.27 |
| Resistance Level | $1.02 | $0.35 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 91.79 | 21.63 |
Price Performance
Historical ComparisonAbout ICG Intchains Group Limited
Intchains Group Ltd is an inventive altcoins development company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies and the active development of inventive Web3 applications. The company offers high-performance mining products including altcoin mining machines incorporating its ASIC chips that have high computing power and superior power efficiency, ASIC chips and ancillary software and hardware, all of which cater to the evolving needs of the blockchain industry. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).